New DNA Testing to Predict the Likelihood of Relapse in Neuroblastoma
About half of all patients have a relapse. The ALK gene determines whether a child will be cured or have a relapse. After treatment it’s possible that there are still some cancerous cells present in the body. These cells grow and multiply causing the child to have the same cancer they were previously treated for. Cancer researchers will use a new high – resolution DNA sequencing when taking samples at the onset of Neuroblastoma and at relapse to identify ALK mutations. Pharmaceutical companies have developed ALK inhibitors to suppress the ALK gene. Would you want your child to participate in this type of DNA testing clinical trials? Do you think it’ll be helpful in combating neuroblastoma relapses? What are your thought and opinions?
Read the full article here. http://www.healthcanal.com/cancers/53733-new-high-resolution-dna-technology-opens-the-door-to-treatment-of-aggressive-childhood-cancer.html
Share this:
